Scalper1 News
The Food and Drug Administration OK’d Gilead Sciences’ (GILD) hepatitis C pill Sovaldi late Friday, an expected but still key step for a drug widely seen as a mega-blockbuster. Analysts foresee a very rapid uptake, with Sovaldi sales of $1.7 billion next year and $8 billion in 2018. That would make it one of the world’s best-selling drugs. Gilead shares edged higher late Friday after closing up 1%. The drug ended up with a Scalper1 News
Scalper1 News